Biologics Spine BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease byTim AllenMay 7, 2026
Biologics Spine BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease byTim AllenFebruary 10, 2026
Biologics Regulatory Spine BioRestorative Granted Type B Meeting with FDA to Discuss Accelerated BLA Approval Pathway for BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergNovember 17, 2025
Biologics Spine BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease byTim AllenJune 13, 2025
Spine BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease byTim AllenApril 8, 2024
Spine BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease byJosh SandbergFebruary 5, 2024
Biologics Spine BioRestorative Therapies Announces Activation of Northwell Health in the Company’s Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease byJosh SandbergSeptember 8, 2023
Biologics BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease byJosh SandbergJune 12, 2023
